Article
The T cell differentiation landscape is shaped by tumour mutations in lung cancer.
Nature cancer - 1 May 2020
Ghorani Ehsan, Reading James L, Henry Jake Y, Massy Marc Robert de, Rosenthal Rachel, Turati Virginia, Joshi Kroopa, Furness Andrew J S, Ben Aissa Assma, Saini Sunil Kumar, Ramskov Sofie, Georgiou Andrew, Sunderland Mariana Werner, Wong Yien Ning Sophia, Mucha Maria Vila De, Day William, Galvez-Cancino Felipe, Becker Pablo D, Uddin Imran, Oakes Theres, Ismail Mazlina, Ronel Tahel, Woolston Annemarie, Jamal-Hanjani Mariam, Veeriah Selvaraju, Birkbak Nicolai J, Wilson Gareth A, Litchfield Kevin, Conde Lucia, Guerra-Assunção José Afonso, Blighe Kevin, Biswas Dhruva, Salgado Roberto, Lund Tom, Bakir Maise Al, Moore David A, Hiley Crispin T, Loi Sherene, Sun Yuxin, Yuan Yinyin, AbdulJabbar Khalid, Turajilic Samra, Herrero Javier, Enver Tariq, Hadrup Sine R, Hackshaw Allan, Peggs Karl S, McGranahan Nicholas, Chain Benny, Swanton Charles, Quezada Sergio A
Abstract excerpt
Tumour mutational burden (TMB) predicts immunotherapy outcome in non-small cell lung cancer (NSCLC), consistent with immune recognition of tumour neoantigens. However, persistent antigen exposure is detrimental for T cell function. How TMB affects CD4 and CD8 T cell differentiation in untreated tumours, and whether this affects patient outcomes is unknown. Here we paired high-dimensional flow cytometry, exome,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.